These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 25739850)

  • 1. How the ESRD quality incentive program could potentially improve quality of life for patients on dialysis.
    Moss AH; Davison SN
    Clin J Am Soc Nephrol; 2015 May; 10(5):888-93. PubMed ID: 25739850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Freestanding Dialysis Facility Quality Incentive Program Scores and Mortality Among Incident Dialysis Patients in the United States.
    Ajmal F; Probst JC; Brooks JM; Hardin JW; Qureshi Z; Jafar TH
    Am J Kidney Dis; 2020 Feb; 75(2):177-186. PubMed ID: 31685294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guiding principles and checklist for population-based quality metrics.
    Krishnan M; Brunelli SM; Maddux FW; Parker TF; Johnson D; Nissenson AR; Collins A; Lacson E
    Clin J Am Soc Nephrol; 2014 Jun; 9(6):1124-31. PubMed ID: 24558050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ESRD Quality Incentive Program-Can We Bridge the Chasm?
    Weiner D; Watnick S
    J Am Soc Nephrol; 2017 Jun; 28(6):1697-1706. PubMed ID: 28298324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes to the end-stage renal disease quality incentive program.
    Fishbane S; Miller I; Wagner JD; Masani NN
    Kidney Int; 2012 Jun; 81(12):1167-71. PubMed ID: 22534963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving adequacy of hemodialysis in Northern California ESRD patients: a final project report. Provider Participants and Medical Review Board of the TransPacific Renal Network.
    Brown J; Josephson M
    Adv Ren Replace Ther; 2000 Oct; 7(4 Suppl 1):S85-94. PubMed ID: 11053593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality Measures for Dialysis: Time for a Balanced Scorecard.
    Kliger AS
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):363-8. PubMed ID: 26316622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New ESRD clinical performance measures and data collection system: progress and pitfalls.
    Wish JB
    Nephrol News Issues; 2008 Jul; 22(8):12-3. PubMed ID: 18711877
    [No Abstract]   [Full Text] [Related]  

  • 9. Meeting the 2012 QIP (Quality Incentive Program) clinical measures: strategies for dialysis centers.
    Fishbane S; Hazzan A
    Am J Kidney Dis; 2012 Nov; 60(5 Suppl 1):S5-13; quiz S14-7. PubMed ID: 23063058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The direction of end-stage renal disease reimbursement in the United States.
    Lockridge RS
    Semin Dial; 2004; 17(2):125-30. PubMed ID: 15043614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Social Risk Factors in Dialysis Quality and Patient Outcomes Under a Medicare Quality Incentive Program.
    Breck A; Marr J; Turenne M; Esposito D
    Med Care; 2022 Oct; 60(10):735-742. PubMed ID: 35880769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESRD Networks: past, present, and challenges for the future.
    Wish JB; Meyer KB
    Clin J Am Soc Nephrol; 2012 Nov; 7(11):1907-14. PubMed ID: 22977212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The QIP: will it improve dialysis care? An overview.
    Fishbane S; Miller I; Danko H; Masani N
    Nephrol News Issues; 2012 Jan; 26(1):20, 22-4, 26. PubMed ID: 22359961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ESRD Quality Incentive Program: The Current Limitations of Evidence and Data to Develop Measures, Drive Improvement, and Incentivize Outcomes.
    Diamond LH; Howard AD
    Adv Chronic Kidney Dis; 2016 Nov; 23(6):377-384. PubMed ID: 28115082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do current quality measures truly reflect the quality of dialysis?
    Gupta N; Wish JB
    Semin Dial; 2018 Jul; 31(4):406-414. PubMed ID: 29482262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The medical director and quality requirements in the dialysis facility.
    Schiller B
    Clin J Am Soc Nephrol; 2015 Mar; 10(3):493-9. PubMed ID: 25376762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perpetuating sub-optimal care: CMS, QIPs, and the hemoglobin myth.
    Pollak SP; Lorch JA; Pollak VE
    Nephrol News Issues; 2012 Jan; 26(1):30, 32-4. PubMed ID: 22359963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the care of ESRD patients: a success story.
    McClellan WM; Frankenfield DL; Frederick PR; Helgerson SD; Wish JB; Sugarman JR
    Health Care Financ Rev; 2003; 24(4):89-100. PubMed ID: 14628402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can dialysis therapy be improved? A report from the ESRD Core Indicators Project.
    McClellan WM; Frankenfield DL; Frederick PR; Flanders WD; Alfaro-Correa A; Rocco M; Helgerson SD
    Am J Kidney Dis; 1999 Dec; 34(6):1075-82. PubMed ID: 10585317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring quality of care at dialysis facilities: a case for regulatory parsimony--and beyond.
    Stivelman JC
    Clin J Am Soc Nephrol; 2012 Oct; 7(10):1673-81. PubMed ID: 22822012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.